Tirzepatide – alternative to CPAP-therapy or new opportunity in the therapy of obstructive sleep apnea?

Sleep-disordered breathing is one of the most common sleep-related disorders. According to basic and clinical research, severe obstructive sleep apnea (OSA) is associated with increased all-cause mortality. Other adverse conditions associated with untreated OSA include cardiovascular disease and its complications, the development of type 2 diabetes, obesity and continued weight gain, cognitive impairment, decreased quality of life, excessive daytime sleepiness, and an increased risk of motor vehicle accidents. Their prevalence tends to increase with age. Tools for accurately diagnosing OSA and treatment options have been developed. Obesity is one of the most significant and independent risk factors for the development of OSA. Weight loss is a key aspect of treating patients with OSA, as it has been shown to improve daytime respiratory failure, pulmonary hypertension, sleep-related breathing parameters, and cardiovascular and metabolic outcomes. This review focuses on the results of the SURMOUNT-OSA trial, which assessed the safety and efficacy of tirzepatide, a drug with incretin activity and the first dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, for the treatment of adults with OSA and obesity. The pathogenic mechanisms of OSA in obesity are discussed based on the latest fundamental research and the mechanisms mediated by tirzepatide. In patients with moderate to severe OSA and obesity, tirzepatide reduced the apneahypopnea index, body weight, hypoxic load, high-sensitivity CRP concentration, and systolic blood pressure, and improved patient-reported sleep-related outcomes.

1. GBD 2021 Risk Factor Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162–2203. https://doi.org/10.1016/S0140--6736(24)00933-4.

2. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and Metabolism. 2022;19(1):96–105. (In Russ.) https://doi.org/10.14341/omet12809.

3. Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med. 2025;6(7):102214. https://doi.org/10.1016/j.xcrm.2025.102214.

4. Zinchuk AV, Gentry MJ, Concato J, Yaggi HK. Phenotypes in obstructive sleep apnea: A definition, examples and evolution of approaches. Sleep Med Rev. 2017;35:113–123. https://doi.org/10.1016/j.smrv.2016.10.002.

5. Butt M, Dwivedi G, Khair O, Lip GY. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol. 2010;139(1):7–16. https://doi.org/10.1016/j.ijcard.2009.05.021.

6. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost. 2011;37(3):280–297. https://doi.org/10.1055/s-0031-1273092.

7. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687–698. https://doi.org/10.1016/S2213-2600(19)30198-5.

8. Jean-Louis G, Brown CD, Zizi F, Ogedegbe G, Boutin-Foster C, Gorga J, McFarlane SI. Cardiovascular disease risk reduction with sleep apnea treatment. Expert Rev Cardiovasc Ther. 2010;8(7):995–1005. https://doi.org/10.1586/erc.10.55.

9. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016;375(10):919–931. https://doi.org/10.1056/NEJMoa1606599.

10. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. Am J Respir Crit Care Med. 2016;194(5):613–620. https://doi.org/10.1164/rccm.201601-0088OC.

11. Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, Abad J, Duran-Cantolla J, Cabriada V et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Respir Med. 2020;8(4):359–367. https://doi.org/10.1016/S2213-2600(19)30271-1.

12. Francis CE, Quinnell T. Mandibular Advancement Devices for OSA: An Alternative to CPAP? Pulm Ther. 2021;7(1):25–36. https://doi.org/10.1007/s41030-020-00137-2.

13. Morgenthaler TI, Kapen S, Lee-Chiong T, Alessi C, Boehlecke B, Brown T et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep. 2006;29(8):1031–1035. Available at: https://pubmed.ncbi.nlm.nih.gov/16944671/.

14. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841–858. https://doi.org/10.1016/j.jacc.2016.11.069.

15. Heinzer R, Eckert D. Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target? Lancet Respir Med. 2020;8(4):323–325. https://doi.org/10.1016/S2213-2600(19)30351-0.

16. Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;144(3):e56–e67. https://doi.org/10.1161/CIR.0000000000000988.

17. Kezirian EJ, Goldberg AN. Hypopharyngeal surgery in obstructive sleep apnea: an evidence-based medicine review. Arch Otolaryngol Head Neck Surg. 2006;132(2):206–213. https://doi.org/10.1001/archotol.132.2.206.

18. Shnayder NA, Petrova MM, Demko IV, Alekseeva OV. Intermediate phenotypes of obstructive sleep apnea/hypopnea syndrome. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):81–86. (In Russ.) https://doi.org/10.14412/2074-2711-2016-4-81-86.

19. Alekseeva O, Shnaider N, Demko I, Petrova M, Zobova S. Obstructive sleep apnea/hypopnea syndrome and obesity. Vrach. 2017;(4):11–14.. (In Russ.) Available at: https://vrachjournal.ru/ru/25877305-2017-04-03.

20. Poluektov MG. Obstructive sleep apnea syndrome: modern concepts and role. Obesity and Metabolism. 2005;2(1):2–7. (In Russ.) https://doi.org/10.14341/2071-8713-4797.

21. Вейн АМ, Елигулашвили ТС, Полуэктов МГ. Синдром апноэ во сне. М.: Эйдос Медиа; 2002. 310 с.

22. Wolk R, Somers VK. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab. 2006;8(3):250–260. https://doi.org/10.1111/j.1463-1326.2005.00508.x.

23. Salukhov VV, Kurenkova IG, Kharitonov MA, Minakov AA. Lung function in obesity. Therapist’s Bulletin. 2022;(3):32–56.. (In Russ.) Available at: https://therapyedu.su/statyi/funkcija-legkih-pri-ozhirenii/

24. Romantsova TR, Sych YuP. Immunometabolism and metainflammation in obesity. Obesity and Metabolism. 2019;16(4):3–17. (In Russ.) https://doi.org/10.14341/omet12218.

25. Fadeeva MI, Savel’eva LV, Fadeev VV. Obstructive sleep apnea syndrome in the practice of an endocrinologist. Obesity and Metabolism. 2010;7(1):3–10. (In Russ.) https://doi.org/10.14341/2071-8713-5271.

26. Shnayder NA, Demko IV, Alekseeva OV, Petrova MM, Kantimirova EA, Strotskaya IG, Diuzhakov SK. Phenotypic and genotypic risk factors for obstructive sleep apnea hypopnea. Problems of Women Health. 2015;10(2):55–64. (In Russ.) Available at: https://www.elibrary.ru/uffeob.

27. Snyder EE, Walts B, Pérusse L, Chagnon YC, Weisnagel SJ, Rankinen T, Bouchard C. The human obesity gene map: the 2003 update. Obes Res. 2004;12(3):369–439. https://doi.org/10.1038/oby.2004.47.

28. Patel SR. Shared genetic risk factors for obstructive sleep apnea and obesity. J Appl Physiol (1985). 2005;99(4):1600–1606. https://doi.org/10.1152/japplphysiol.00501.2005.

29. Litvin AYu, Chazova IE, Elfimova EM, Pevzner AV, Poluektov MG, Danilov NM et al. Eurasian association of cardiology (EAC) / Russian society of somnologists (RSS) guidelines for the diagnosis and treatment of obstructive sleep apnea in patients with cardiovascular diseases (2024). Eurasian Heart Journal. 2024;(3):6–27. (In Russ.) https://doi.org/10.38109/2225-1685-2024-3-6-27.

30. Begrambekova YuL, Karanadze NA, Orlova YaA. Alterations of the respiratory system in heart failure. Kardiologiia. 2019;59(2S):15–24. (In Russ.) https://doi.org/10.18087/cardio.2626.

31. Ostroumova OD, Isaev RI, Kotovskaya YuV, Tkacheva ON. Drugs affecting obstructive sleep apnea syndrome. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(9):46–54. (In Russ.) https://doi.org/10.17116/jnevro202012009146.

32. Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, Murphy PB, Piper AJ еt аl. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(3):e6–e24. https://doi.org/10.1164/rccm.201905-1071ST.

33. Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC еt аl. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1–7. https://doi.org/10.1016/j.amjmed.2003.08.022.

34. Bikova OV, Kusenkova LM, Maslova OI, Boyko AN. Acetazolamide in the treatment of sleep apnea m adults and childi en. Arterial Hypertension (Russian Federation). 2006;12(4):365–368. (In Russ.) https://doi.org/10.18705/1607-¬419X-2006-12-4-365-368.

35. Masa JF, Corral J, Caballero C, Barrot E, Terán-Santos J, Alonso-Álvarez ML еt аl. Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea. Thorax. 2016;71(10):899–906. https://doi.org/10.1136/thoraxjnl-2016-208501.

36. Kakazu MT, Soghier I, Afshar M, Brozek JL, Wilson KC, Masa JF, Mokhlesi B. Weight Loss Interventions as Treatment of Obesity Hypoventilation Syndrome. A Systematic Review. Ann Am Thorac Soc. 2020;17(4):492–502. https://doi.org/10.1513/AnnalsATS.201907-554OC.

37. Afshar M, Brozek JL, Soghier I, Kakazu MT, Wilson KC, Masa JF, Mokhlesi B. The Role of Positive Airway Pressure Therapy in Adults with Obesity Hypoventilation Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2020;17(3):344–360. https://doi.org/10.1513/AnnalsATS.201907-528OC.

38. Masa JF, Pépin JL, Borel JC, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151):180097. https://doi.org/10.1183/16000617.0097-2018.

39. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009.

40. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. https://doi.org/10.1056/NEJMoa2206038.

41. Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obes Metab. 2022;24(1):148–153. https://doi.org/10.1111/dom.14553.

42. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193–1205. https://doi.org/10.1056/NEJMoa2404881.

43. Lugovik IA, Babina AV, Arutyunyan SS, Ermolaeva DO, Saparova VB, Kobeleva TN et al. The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug. Drug Development and Registration. 2025;14(2):54–74. (In Russ.) https://doi.org/10.33380/2305-2066-2025-14-2-2084.